NUGX 0.00 NuGenerex Immuno-Oncology, Inc.
| Range: | 1.0E-5-0.3 | Vol Avg: | 122 | Last Div: | 0 | Changes: | 0 |
| Beta: | 142.69 | Cap: | 0.00B | Currency: | USD | Exchange: | OTC |
| Sector: | Healthcare | IPO: | Mon Mar 15 2021 | Empoloyees: | 6 | ||
| CUSIP: | 67053X102 | CIK: | 0001804585 | ISIN: | US67053X1028 | Country: | US |
| CEO: | Mr. Joseph Moscato | Website: | https://www.generex.com | ||||
NuGenerex Immuno-Oncology, Inc., an oncology company, focuses on the modulation of the immune system to treat cancer. The company is developing immunotherapeutic products and vaccines. It is developing AE37, a peptide immunotherapeutic vaccine, which is in Phase II clinical trials for the treatment of metastatic triple negative breast cancer. The company was formerly known as Antigen Express, Inc. The company was founded in 1993 and is based in Miramar, Florida. NuGenerex Immuno-Oncology, Inc.is a subsidiary of Generex Biotechnology Corporation.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow